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Introduction
Orthostatic tremor is a rare condition, characterized by unsteadiness 
while standing but relieved when sitting, walking, or lying down. Diagnosis 
is based on electromyography (EMG), which reveals a 13–18 Hz fast 
tremor in the legs, and occasionally in the trunk and arms as well.1 
Neuroimaging and laboratory testing are typically unremarkable in pri-
mary orthostatic tremor (POT).2 Cases of  secondary orthostatic tremor 
due to brainstem/cerebellar lesions, paraneoplastic disease, autoimmune 
causes, vitamin deficiencies, and side effects to dopamine-blocking medi-
cations have been reported.2 Various pathophysiologic mechanisms for 
POT have been postulated. These include the presence of  a central oscil-
lator in the brainstem and/or cerebellum, and the possibility of  POT 
being a neurodegenerative condition.2
POT continues to remain a therapeutic conundrum. Evidence sup-
ports the use of  various medication classes such as benzodiazepines, beta 
blockers, and antiepileptic agents.3 However, results remain modest at 
best. To date, there has only been one case report of  marked improvement 
of  symptoms using perampanel.4 We present a case that re-demonstrates 
similar findings using perampanel for the treatment of  this condition, at 
doses that are subtherapeutic for the treatment of  epilepsy.
Case report
A 62-year-old female with a history significant for adrenal insufficiency 
had a 13-year history of  instability and tremors in her legs when standing 
that improved when walking but caused her to have an overwhelming 
urge to sit or lie down. She had been previously diagnosed at an outside 
facility with orthostatic tremor within a year of  symptom onset with sur-
face EMG revealing 17–18 Hz tremor in her legs and back when standing. 
When she walked, the tremor ‘’went away significantly’’ per the report. 
When she leaned on a chair, the tremor was noted in her arms.
Other investigations included MRI brain which had revealed T2 hyper-
intense lesions in the periventricular white matter. MRI C- and T-spine did 
not demonstrate any lesions. CSF analysis was negative for oligoclonal 
bands when tested on two separate occasions, 6 years apart. CSF was 
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Background:  Primary orthostatic tremor (POT) remains a therapeutic conundrum. Various medication classes have been tried, yielding modest results at best.
Case Report:  A 62-year-old female with a 13-year history of  POT, refractory to clonazepam up to 20 mg/day, was treated with perampanel 1–2 mg/day. She 
reported 90% subjective symptomatic improvement.
Discussion:  This case highlights the potential for use of  perampanel, a novel AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist 
for the treatment of  POT. There has been one prior report citing its use for POT with complete resolution of  symptoms. We encourage further studies to highlight 
its efficacy for POT.
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otherwise unremarkable, including negative VDRL and Lyme titers. 
Serum studies were remarkable for elevated EBV IgG titers and a homo-
zygous MTHFR mutation, which were obtained as part of  workup for 
the white matter lesions on MRI brain. Titers for CMV, ANA, RF, SSA, 
SSB, Babesia, and Lyme antibodies were negative. Vitamin D and TSH 
levels were within normal limits. She reported a history of  depression 
related to her disability from the orthostatic tremor.
She had been treated with clonazepam, up to 20 mg/day, without 
any symptomatic benefit. She subsequently had it tapered down to 
0.25 mg/day. She requested a trial of  perampanel citing the report by 
Ruiz-Julian et al.4 We started her on perampanel 2 mg/day after coun-
seling on possible psychiatric side effects, and the patient returned for 
follow-up on 1 mg/day with an additional 1 mg/day as needed (rarely). 
She immediately reported significant subjective symptomatic improve-
ment, up to 90%. She did not report any side effects. Repeat needle 
EMG testing showed persistence of  17–18 Hz tremor when standing. 
Amplitude and burst synchronicity comparisons could not be made 
given differences in EMG techniques (surface vs. needle) and those char-
acteristics not noted on her previous EMG done at an outside facility.
Discussion
Orthostatic tremor presents significant motor as well as non-motor 
challenges to affected patients. While instability on standing and tremor 
are hallmarks of  this disorder, symptoms such as fear of  falling, social 
phobia, anxiety, and depression are also common and cause significant 
morbidity.5 Due to its rare nature, there has been a dearth of  well- 
designed randomized controlled trials.2 Of  the medications that have 
been trialed, clonazepam has been shown to be the most beneficial. 
However, on a retrospective chart review of  184 patients, clonazepam 
provided at least a mild benefit in 55% of  the patients, followed by 
 gabapentin (33%).3 Other medication groups tried with lesser success 
were other antiepileptics and benzodiazepines, beta blockers, anti- 
Parkinsonian medications, antispasmodics, anticholinergics, antidepres-
sants, calcium channel blockers, and carbonic anhydrase inhibitors.
Based on our review of  literature, there has only been one reported 
case of  perampanel (2–4 mg/day) used for POT which led to complete 
resolution of  symptoms.4 Our case replicates the findings with signifi-
cant symptomatic benefit at a lower dose (1–2 mg/day).
Perampanel is a first-in-class, high potency, orally active, non- 
competitive AMPA receptor antagonist.6 Fast glutamatergic neurotrans-
mission is primarily mediated by postsynaptic AMPA and NMDA 
receptors. By blocking the former, perampanel inhibits glutamate- 
mediated excitation. As a result, it has been successfully used as an 
antiepileptic agent for both focal onset and generalized epilepsy. The 
half-life is long (105 hours) which argues against its use as an as-needed 
medication, despite our patient’s experience.
Gironell and Marin-Lahoz have proposed that an increase in excit-
atory neurotransmitter activity could be an underlying mechanism 
for essential tremor (ET).7 Increased input to the deep nuclei of  the 
cerebellum could induce oscillatory activity and subsequently propagate 
to  thalamic nuclei and the motor cortex. While ET and POT are dis-
tinct entities, the role of  a central oscillator has been proposed as an 
underlying mechanism for both. One possible mechanism for peram-
panel’s effect in POT is interference with glutamatergic neurotransmis-
sion to central oscillators; perampanel may therefore be a valuable 
treatment option in other forms of  tremors, such as ET.8
It is interesting to note that our patient did not have complete resolu-
tion of  POT on electromyography nor any change in frequency follow-
ing treatment with perampanel. This duplicates the findings of  
Ruiz-Julian et al. and raises the possibility that modulating glutamate 
only has a dampening effect on the symptoms of  POT, perhaps by 
reducing the amplitude rather than the frequency of  tremor, as postu-
lated previously, although this could not be confirmed as amplitude 
comparisons were not available.4
Perampanel has a black box warning based on studies in epilepsy for 
serious neuropsychiatric side effects, including major depression and sui-
cidal and homicidal thoughts. Our patient and many patients with POT 
have psychiatric disorders, in some cases as a reaction to the physical 
limitations of  the disease. It is important to counsel patients on this 
potential concern. It is worth noting that dosing of  perampanel for epi-
lepsy is 2–12 mg/day; our case demonstrates efficacy at lower doses, and 
it is not known whether the risk of  side effects is similar at those doses.
In conclusion, perampanel offers a novel strategy to combat POT. 
Given the now reproducible evidence of  significant symptomatic 
improvement in POT, it would be reasonable to consider an early ther-
apeutic trial of  this medication rather than having patients accrue years 
of  morbidity while cycling through other medications, which have thus 
far yielded suboptimal results. Of  course, the possibility of  a placebo 
effect is present, especially as the patient requested the medication. 
Therefore, blinded, placebo-controlled trials to establish its efficacy, dos-
ing requirements, and side effect profile at those doses are recommended 
to further our understanding of  optimal treatment for these patients.
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